Context:
• The BioPharma SHAKTI initiative, announced in the Union Budget 2026, aims to strengthen India’s biologics and biosimilars ecosystem by promoting non-animal methodologies (NAMs) in drug development.
Key Highlights:
- Government Initiative / Policy Details
• BioPharma SHAKTI with an allocation of ₹10,000 crore aims to boost domestic manufacturing of biologics and biosimilars
• Encourages adoption of Non-Animal Methodologies (NAMs) such as organoids and organ-on-chip systems
• Supported by New Drugs and Clinical Trials (Amendment) Rules, 2023, enabling NAM-based testing - Scientific Principle / Technological Insights
• NAMs simulate human biological systems more accurately than animal models
• Technologies include:
– Organoids (miniature lab-grown organs)
– Organ-on-a-chip (microfluidic systems mimicking organ functions) - Data / Evidence / Case Facts
• Northwick Park Trial (2006) exposed failure of animal testing in predicting human immune responses
• NAMs can:
– Reduce drug development cost by 10–26%
– Reduce lead optimization time by ~19% - Stakeholders Involved
• Pharmaceutical companies
• Academic and research institutions
• Regulatory bodies (CDSCO)
• Biotech investors and startups - Significance / Applications
• Improves drug safety and efficacy prediction
• Reduces ethical concerns related to animal testing
• Strengthens India’s position in global biologics market
• Promotes innovation-driven pharmaceutical sector - Challenges / Concerns
• Patent evergreening limits biosimilar market access
• Slow regulatory approvals by CDSCO
• Low investor awareness and funding gaps
• Weak supply chain and infrastructure support
Relevant Prelims Points:
- Biologics:
– Complex drugs derived from living organisms
– Used in treating diseases like cancer, autoimmune disorders - Biosimilars:
– Follow-on versions of biologics after patent expiry
– Not identical but highly similar in efficacy and safety - Non-Animal Methodologies (NAMs):
– Alternatives to animal testing using human cell-based systems
– Examples: organoids, organ-on-chip, in-silico models - CDSCO (Central Drugs Standard Control Organisation):
– India’s national regulatory authority for pharmaceuticals - Patent Evergreening:
– Strategy to extend patent life via minor modifications in drugs
Relevant Mains Points:
- Role of BioPharma SHAKTI in strengthening India’s biotech sector:
– Promotes self-reliance (Atmanirbhar Bharat) in high-value biologics
– Reduces dependency on imported biologic drugs
– Enhances global competitiveness of Indian pharma - Importance of NAMs in drug development:
– Provides human-relevant data, improving clinical success rates
– Reduces time and cost inefficiencies
– Aligns with global ethical standards (3Rs: Replace, Reduce, Refine animal use) - Regulatory and market challenges:
– Need for faster approvals and adaptive regulatory frameworks
– Addressing patent barriers to encourage biosimilars
– Bridging funding and knowledge gaps in emerging biotech technologies - Economic and innovation impact:
– Potential to make India a hub for affordable biologics
– Encourages public-private partnerships
– Supports startup ecosystem in biotech - Way Forward:
– Develop clear CDSCO guidelines for NAM adoption
– Increase R&D funding and investor awareness
– Strengthen biotech infrastructure and supply chains
– Promote international collaboration and regulatory harmonization
UPSC Relevance:
• GS 3: Biotechnology, Innovation, Indigenization of Technology
• GS 2: Governance, Regulatory Frameworks
• GS 3: Economic Development, Pharmaceutical Sector